Medindia

X

The Female Health Company Confirms Guidance for FY Ended September 30, 2008

Friday, November 7, 2008 General News J E 4
Advertisement
CHICAGO, Nov. 6 The Female Health Company(Amex: FHC) which manufactures and markets the FC and FC2 Female Condoms(R),today confirmed its guidance for the fiscal year ended September 30, 2008.

"We are very pleased to confirm that our August 2008 guidance regardingfiscal year 2008 growth in units and pre-tax income was on target." noted O.B.Parrish, Chief Executive Officer of The Female Health Company. "Growingglobal acceptance of the female condom as the only available FDA approvedbarrier contraceptive method controlled by women that provides protectionagainst HIV/AIDS is the basis for our growth. The FC Female Condom is nowavailable in over 100 countries, and we believe it will play an increasinglyimportant role in the global battle against HIV/AIDS in the future."

"In August 2008, we confirmed our previous sales guidance of 20% to 25%growth in units over the fiscal year 2007 level of 25.9 million units. At thattime, we increased the pretax income guidance to be an increase of 200% to250% over the FY2007 pre-tax income of $868,913. We now reaffirm thatguidance."

"We are optimistic regarding the outlook for The Female Health Company.Our team members are now working with organizations in nearly all regions ofthe world, from Brazil to Cambodia, from the United Kingdom to India, from NewYork to South Africa. Given the gravity of the HIV/AIDS pandemic, our resultsare an indicator of the even greater contribution the female condom will maketo world health in coming years," concluded Parrish.

About The Female Health Company

The Female Health Company (FHC), headquartered in Chicago, IL, is themaker of the FC Female Condom (FC1 and FC2), a revolutionary option offeringwomen dual protection against both sexually transmitted diseases, includingHIV/AIDS, and unintended pregnancy. FHC was created as a worldwide company inFebruary 1996 with the purchase of Chartex Resources Ltd., the holder ofexclusive worldwide rights to FC1. The Company holds exclusive product andtechnology patents for FC1 in the United States, Australia, Brazil, Canada,France, Germany, Italy, Spain, the United Kingdom, the People's Republic ofChina, South Korea and Japan. Patents are pending for FC2. FHC is the solemanufacturer and marketer of the FC1 and FC2 female condoms in the world.

The Female Health Company and its partners currently market the FemaleCondom under FC Female Condom(R), FC2 Female Condom(R), Reality(R),Femidom(R), Femy(R), and Care(R) in the rest of the world.

For more information about the Female Health Company visit the Company'swebsite at http://www.femalehealth.com and http://www.femalecondom.org . Ifyou would like to be added to the Company's e-mail alert list, please send ane-mail to FHCInvestor@femalehealthcompany.com .

"Safe Harbor" statement under the Private Securities Litigation Reform Actof 1995:

The statements in this release which are not historical fact are"forward-looking statements" as that term is defined in the Private SecuritiesLitigation Reform Act of 1995. Forward-looking statements in this releaseinclude the Company's financial guidance for fiscal 2008. These statementsare based upon the Company's current plans and strategies, and reflect theCompany's current assessment of the risks and uncertainties related to itsbusiness, and are made as of the date of this release. The Company assumes noobligation to update any forward-looking statements contained in this releaseas a result of new information or future events, developments orcircumstances. Such forward-looking statements are inherently subject toknown and unknown risks and uncertainties. The Company's actual results andfuture developments could differ materially from the results or developmentsexpressed in, or implied by, these forward-looking statements. Factors thatmay cause actual results to differ materially from those contemplated by suchforward-looking statements include, but are not limited to, the following:product demand and market acceptance; competition in the Company's markets andthe risk of new competitors and new competitive product introductions; theCompany's reliance on its international partners in the consumer sector and onthe level of spending on the female condom by country governments, globaldonors and other public health organizations in the global public sector; theeconomic and business environment and the impact of government pressures;risks involved in doing business on an international level, including currencyrisks, regulatory requirements, political risks, export restrictions and othertrade barriers; the Company's production capacity; efficiency and supplyconstraints; and other risks detailed in the Company's press releases,shareholder communication and Securities and Exchange Commission filings,including the Company's Form 10-KSB for the fiscal year ended September 30,2007. Actual events affecting the Company and the impact of such events on theCompany's operations may vary from those currently anticipated.

SOURCE Female Health Company
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
VIA Pharmaceuticals Announces Conference Call and ...
S
HCA Reports Third Quarter 2008 Results